6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers

References

• Mitscher LA, Pillai SP, Gentry EJ, et al. Multiple drug resistance. Med Res Rev 1999;19:477–96.
   PubMed Web of Science ®Google Scholar
• Kaye SB. The multidrug resistance phenotype. Br J Cancer 1988;58:691–4.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi T, Zhang L, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 2016;370:153–64.
   PubMed Web of Science ®Google Scholar
• El-Awady R, Saleh E, Hashim A, et al. The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy. Front Pharmacol 2017;7:535.
   PubMedGoogle Scholar
• Altenberg GA. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr Med Chem Anticancer Agents 2004;4:53–62.
   PubMedGoogle Scholar
• Loo TW, Clarke DM. Mutational analysis of ABC proteins. Arch Biochem Biophys 2008;476:51–64.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152–62.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105–27.
   PubMed Web of Science ®Google Scholar
• McGrath T, Center MS. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 1988;48:3959–63.
   PubMed Web of Science ®Google Scholar
• (a) Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994;54:5902–10.
   PubMed Web of Science ®Google Scholar
  (b) Grant CE, Valdimarsson G, Hipfner DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54:357–61.
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665–70.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 2012;31:73–99.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Assaraf YG, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat 2016;27:14–29.
   PubMed Web of Science ®Google Scholar
• Videira M, Reis RL, Brito MA. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochim Biophys Acta 2014;1846:312–25.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216–37.
   PubMed Web of Science ®Google Scholar
• Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546–53.
   PubMed Web of Science ®Google Scholar
• Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004;10:1691–7.
   PubMed Web of Science ®Google Scholar
• Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014;20:793–807.
   PubMed Web of Science ®Google Scholar
• Kathawala RJ, Gupta P, Ashby CR Jr, et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 2015;18:1–17.
   PubMed Web of Science ®Google Scholar
• Teodori E, Dei S, Martelli C, et al. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 2006;7:893–909.
   PubMed Web of Science ®Google Scholar
• Yang K, Wu J, Li X. Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2008;2:137–46.
   PubMed Web of Science ®Google Scholar
• Lhommé C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008;26:2674–82.
   PubMed Web of Science ®Google Scholar
• Kolitz JE, George SL, Marcucci G, et al.; for the Cancer and Leukemia Group B. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413–21.
   PubMed Web of Science ®Google Scholar
• Myer MS, Joone G, Chasen MR, et al. The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol Rep 1999;6:217–8.
   PubMed Web of Science ®Google Scholar
• Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007;7:447–59.
   PubMed Web of Science ®Google Scholar
• Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10:159–65.
   PubMedGoogle Scholar
• Coley HM. Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors. Methods Mol Biol 2010;596:341–58.
   PubMedGoogle Scholar
• Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010;116:4077–85.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011;17:569–80.
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012;19:1946–2025.
   PubMed Web of Science ®Google Scholar
• Kühnle M, Egger M, Müller C, et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009;52:1190–7.
   PubMed Web of Science ®Google Scholar
• Kakarla P, Inupakutika M, Devireddy AR, et al. 3D-QSAR and contour map analysis of tariquidar analogues as multidrug resistance protein-1 (MRP1) inhibitors. Int J Pharm Sci Res 2016;7:554–72.
   PubMed Web of Science ®Google Scholar
• Sun YL, Chen JJ, Kumar P, et al. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS One 2013;8:e55576.
   PubMed Web of Science ®Google Scholar
• Teodori E, Dei S, Bartolucci G, et al. Structure-activity relationship studies on 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline derivatives as multidrug resistance reversers. ChemMedChem 2017;12:1369–79.
   PubMed Web of Science ®Google Scholar
• Orlandi F, Coronnello M, Bellucci C, et al. New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). Bioorg Med Chem 2013;21:456–65.
   PubMed Web of Science ®Google Scholar
• Teodori E, Dei S, Coronnello M, et al. N-alkanol-N-cyclohexanol amine aryl esters: multidrug resistance (MDR) reversing agents with high potency and efficacy. Eur J Med Chem 2017;127:586–98.
   PubMed Web of Science ®Google Scholar
• Teodori E, Dei S, Floriddia E, et al. Arylamino esters As P-glycoprotein modulators: SAR studies to establish requirements for potency and selectivity. ChemMedChem 2015;10:1339–43.
   PubMed Web of Science ®Google Scholar
• Dei S, Coronnello M, Floriddia E, et al. Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters. Eur J Med Chem 2014;87:398–412.
   PubMed Web of Science ®Google Scholar
• Martelli C, Dei S, Lambert C, et al. Inhibition of P-glycoprotein-mediated Multidrug Resistance (MDR) by N,N-bis(cyclohexanol)amine aryl esters: further restriction of molecular flexibility maintains high potency and efficacy. Bioorg Med Chem Lett 2011;21:106–9.
   PubMed Web of Science ®Google Scholar
• Dei S, Budriesi R, Sudwan P, et al. Diphenylcyclohexylamine derivatives as new potent multidrug resistance (MDR) modulators. Bioorg Med Chem 2005;13:985–98.
   PubMed Web of Science ®Google Scholar
• Marshall AG, Hendrickson CL. High-resolution mass spectrometers. Annu Rev Anal Chem (Palo Alto Calif) 2008;1:579–99.
   PubMed Web of Science ®Google Scholar
• Das R, Chakraborty D. Cu(II) bromide catalyzed oxidation of aldehydes and alcohols. Appl Organometal Chem 2011;25:437–42.
   Web of Science ®Google Scholar
• Ohnmacht CJ. N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists. US 6403601B1. 2002.
   Google Scholar
• Kowanko N, Leete E. Biosynthesis of the cinchona alkaloids. I. The incorporation of tryptophan into quinine. J Am Chem Soc 1962;84:4919–21.
   Web of Science ®Google Scholar
• Riganti C, Miraglia E, Viarisio D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 2005;65:516–25.
   PubMed Web of Science ®Google Scholar
• Capparelli E, Zinzi L, Cantore M, et al. SAR Studies on tetrahydroisoquinoline derivatives: The role of flexibility and bioisosterism to raise potency and selectivity toward P-glycoprotein. J Med Chem 2014;57:9983–94.
   PubMed Web of Science ®Google Scholar
• Polli JW, Wring SA, Humphreys JE, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2002;303:1029–8.
   PubMed Web of Science ®Google Scholar
• Inglese C, Perrone MG, Berardi F, et al. Modulation and absorption of xenobiotics: the synergistic role of CYP450 and P-gp activities in cancer and neurodegenerative disorders. Curr Drug Metab 2011;12:702–12.
   PubMed Web of Science ®Google Scholar
• Colabufo NA, Contino M, Cantore M, et al. Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters. Bioorg Med Chem 2013;21:1324–32.
   PubMed Web of Science ®Google Scholar
• Kangas L, Grönroos M, Nieminen AL. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984;62:338–43.
   PubMedGoogle Scholar
• Feng B, Mills JB, Davidson RE, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008;36:268–75.
   PubMed Web of Science ®Google Scholar
• Teodori E, Dei S, Garnier-Suillerot A, et al. Structure-activity relationship studies on the potent multidrug resistance (MDR) modulator 2-(3,4-dimethoxyphenyl)-2-(methylethyl)-5-[anthr-9-yl)methylamino]pentanenitrile (MM36). Med Chem Res 2001;10:563–76.
   Web of Science ®Google Scholar
• Riganti C, Kopecka J, Panada E, et al. The role of C/EBP-β LIP in multidrug resistance. J Natl Cancer Inst 2015;107:pii: djv046.
   PubMedGoogle Scholar
• Kopecka J, Campia I, Jacobs A, et al. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget 2015;6:6776–93.
   PubMed Web of Science ®Google Scholar
• Dei S, Braconi L, Trezza A, et al. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. Eur J Med Chem 2019;172:71–94.
   PubMed Web of Science ®Google Scholar